<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797652</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-BREAST-CTDNA</org_study_id>
    <nct_id>NCT02797652</nct_id>
  </id_info>
  <brief_title>Clinical Application of CTDNA in Operable Breast Cancer Patients</brief_title>
  <official_title>Clinical Application of CTDNA in Operable Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <brief_summary>
    <textblock>
      Our study aims to evaluate the possibility of clinical application of CTDNA detection in
      samples or peripheral blood of breast cancer patients, so as to act as the new techniques or
      indicators of early diagnosis, therapy efficiency, or postoperative surveillance of breast
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of ctDNA copies per milliliter in patients' peripheral blood</measure>
    <time_frame>2 years</time_frame>
    <description>The number of ctDNA copies per milliliter in patients' peripheral blood of neoadjuvant chemotherapy group and surgery group in different periods</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <description>ctDNA of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <description>ctDNA of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy before surgery</intervention_name>
    <description>The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery followed by adjuvant chemotherapy</intervention_name>
    <description>The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Operable breast cancer patients who need chemotherapy before or after surgery.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent must be obtained and documented according to the local
             regulatory requirements prior to beginning specific protocol procedures.

          2. Age of at least 18 and at most 70 years.

          3. Performance status (Karnofsky-Index) ＞80%.

          4. Chemotherapy is necessary before or after surgery.

          5. No clinical evidence of local recurrence or distant metastases.

          6. Complete staging work-up within 3 months prior to registration. All patients must have
             (bilateral) mammography or breast MRI, chest X-ray; other tests may be performed as
             clinically indicated.

          7. Life expectancy of at least 2 years, disregarding the diagnosis of cancer.

          8. Adequate organ function including normal red and white blood count, platelets, serum
             creatinine, bilirubin, and transaminases within normal range of the institution.

          9. Patients must be available for and compliant to treatment and follow-up.

         10. Patients registered on this trial must be treated and followed up at the participating
             center.

        Exclusion Criteria:

          1. Known hypersensitivity reaction to the investigational compounds or incorporated
             substances.

          2. Local recurrence and/or metastasis of breast cancer.

          3. No need of chemotherapy.

          4. Pregnant or lactating patients. Patients of childbearing potential must have a
             negative pregnancy test (urine or serum) within 14 days prior to registration.

             Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or
             carcinoma in situ of the uterine cervix)

          5. Any other serious medical pathology, such as congestive heart failure; unstable
             angina; history of myocardial infarction during the previous year; uncontrolled high
             risk arrhythmias

          6. Other serious illness or medical condition that may interfere with the understanding
             and giving of informed consent and the conduct of the study.

          7. Concurrent treatment with other experimental drugs or any other anti-cancer therapy.

          8. Males.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Sun, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Sun, Doctor</last_name>
    <phone>86-010-69152701</phone>
    <email>sunqiangpumc@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Peng, Doctor</last_name>
    <phone>86-010-69152701</phone>
    <email>pl226@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Sun, Doctor</last_name>
      <phone>86-010-69152701</phone>
      <email>sunqiangpumc@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Peng, Doctor</last_name>
      <phone>86-010-69152701</phone>
      <email>pl226@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yidong Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Peng, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi: 10.1038/nrclinonc.2013.110. Epub 2013 Jul 9. Review.</citation>
    <PMID>23836314</PMID>
  </reference>
  <reference>
    <citation>Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013 Mar 28;368(13):1199-209. doi: 10.1056/NEJMoa1213261. Epub 2013 Mar 13.</citation>
    <PMID>23484797</PMID>
  </reference>
  <reference>
    <citation>Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.</citation>
    <PMID>26311728</PMID>
  </reference>
  <reference>
    <citation>Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, Lamy P, Kannerup AS, Mortensen FV, Stribolt K, Hamilton-Dutoit S, Nielsen HJ, Laurberg S, Pallisgaard N, Pedersen JS, Ørntoft TF, Andersen CL. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016 Apr;65(4):625-34. doi: 10.1136/gutjnl-2014-308859. Epub 2015 Feb 4.</citation>
    <PMID>25654990</PMID>
  </reference>
  <reference>
    <citation>Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct;5(10):1040-8. doi: 10.1158/2159-8290.CD-15-0274. Epub 2015 Jun 24.</citation>
    <PMID>26109333</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>June 11, 2016</last_update_submitted>
  <last_update_submitted_qc>June 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Qiang SUN</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>ctDNA</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

